Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Reuters9d
Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
"We are working to make Wegovy (semaglutide injection 2.4 milligrams) available as soon as possible. We do not yet have a confirmed date for launch," Novo India said in a statement to Reuters.
The Independent7d
Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says
open image in gallery An injection pen of Zepbound, Eli Lilly’s weight loss drug, is seen next to boxes of Novo Nordisk’s Wegovy earlier this year. Novo Nordisk said it would wait for the ...
The Victoria Advocate8d
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
The most commonly reported adverse events in SURMOUNT-5 for both Zepbound and Wegovy were gastrointestinal ... indigestion, injection site reactions, feeling tired, allergic reactions, belching ...
Yahoo Finance9d
Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
"We are working to make Wegovy (semaglutide injection 2.4 milligrams) available as soon as possible. We do not yet have a confirmed date for launch," Novo India said in a statement to Reuters.
FOX59 News8d
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint ... pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn.